Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants

Published on
Journal: Nanoscale
[저자] Kevin M Tuffy, Bahar Ahani, Anastasia A Aksyuk, Miles Avila, Tyler Brady, Gustavo H Kijak, Gavin Koh, Myron J Levin, Tiffany L Roe, Nicolette Schuko, Jesse Thissen, Andrew Ustianowski, Tianhui Zhang, Elizabeth J Kelly, Katie Streicher
[Category] update2024,
PMC URL    Pubmed URL    DOI URL    [DOI] 10.1093/infdis/jiad210    
[Article Type] Brief Report
[Source] PMC

Symptomatic COVID-19 breakthrough cases in the PROVENT preexposure prophylaxis trial were not due to resistance-associated substitutions in AZD7442 (tixagevimab/cilgavimab) binding sites or lack of AZD7442 exposure.

All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, monoclonal antibody, viral neutralization, AZD7442, Tixagevimab, Viral resistance, cilgavimab,